A new male birth control method called ADAM has begun Phase 2 trials in Australia, developed by the U.S. biotech firm Contraline. This innovative non-hormonal hydrogel is injected into the vas deferens, the tube that carries sperm, blocking sperm flow for up to two years. The procedure takes about 10 minutes and does not affect testosterone levels, distinguishing it from traditional hormonal contraceptives. Early trials have shown effective sperm blockage without significant side effects. Although ADAM is designed to be reversible, researchers are still collecting long-term data on its reversibility and overall safety. If successful, ADAM could provide men with a temporary alternative to vasectomy. The ongoing trials aim to assess its long-term effectiveness and safety in a broader male population.
